Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients

Ozen M., Gunduz M., ATEŞ Ö., BABACAN T., SEVER A. R. , AKIN S., ...More

JOURNAL OF BUON, vol.21, no.4, pp.799-808, 2016 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 4
  • Publication Date: 2016
  • Journal Name: JOURNAL OF BUON
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.799-808

Abstract

Purpose: Optimal duration of adjuvant trastuzumab therapy in early-stage HER2-positive, lymph node-negative breast cancer is unknown. To establish this, we compared 1-year and 9-week trastuzumab regimens in HER2-positive, lymph node-negative early-stage breast cancer patients.